Navigation Links
AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
Date:9/25/2008

QUEBEC CITY, Sept. 25 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its President and CEO, Jrgen Engel, PhD, will present a company overview at BioContact Quebec on Thursday, October 2, 2008, at 2:00 pm (eastern time) in the Salle Frontenac of the Fairmont Le Chateau Frontenac hotel in Quebec City, Canada.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at http://www.aezsinc.com.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
2. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
3. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
4. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
5. AEterna Zentaris Sells Quebec City Building for $7.1 million
6. AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting
7. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
8. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
9. AEterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008
10. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
11. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... April 27, 2017  Pendant Biosciences, Inc. (formerly Nanoferix, ... modification and drug delivery technologies, today announced that it ... @ Toronto . ... Pendant Biosciences, noted, "We are excited to become part ... community, and are honored to be the first ...
(Date:4/26/2017)... ... 26, 2017 , ... Looking for gift ideas for mom ... offers one-of-a-kind gifts, ranging from gourmet cooking experiences to Farmer’s Market Tours and ... inspired with new cooking tips and techniques, thanks to Chef Jodi Abel’s expertise ...
(Date:4/26/2017)... ... April 26, 2017 , ... Led by ex-FDA official ... trials comes to Tampa, San Francisco and Boston in 2017. The 2016 ... organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., Ocular Therapeutix Inc., Cell ...
(Date:4/26/2017)... ... April 26, 2017 , ... Baltimore bio tech firm, PathSensors, ... screening solution at the National Postal Forum 2017 in Baltimore, Maryland, May 21st ... accurate, easy to use and low cost threat detection solution for government and ...
Breaking Biology Technology:
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 15.1% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
Breaking Biology News(10 mins):